June 20, 2026 a 09:00 pm

AMGN: Analysts Ratings - Amgen Inc.

Historical Stock Grades

The historical ratings for Amgen Inc. display a stable trend in the number of ratings since early 2026, but there's a noticeable steadying in the 'Hold' category, suggesting a careful assessment of the company's potential in current market conditions.

Rating	Count	Score
Strong Buy	4
Buy	10
Hold	18
Sell	2
Strong Sell	1

Sentiment Development

Amgen Inc.'s analysts ratings over the past months indicate a burgeoning cautious sentiment, with 'Hold' ratings consistently dominating the category. Although the number of 'Buy' ratings saw fluctuations, a general hesitance remains palpable regarding any strong bullish moves.

• The total number of recommendations has maintained equilibrium, showing slight increments in the 'Hold' category.
• 'Strong Buy' ratings saw a minor decline, with the focus dispersing toward less aggressive stances.

Percentage Trends

The percentage distribution of ratings illustrates a substantial commitment to caution over the last several months, with 'Hold' composing nearly half of the total ratings in recent evaluations. Such proportions suggest analysts are weighing potential market factors more critically, shifting from aggressive endorsements to restrained outlooks.

• As of June 2026, 'Strong Buy' indicates a mere 10%, reflecting a pullback from more optimistic outlooks noted back in early 2025.
• 'Hold' ratings have crept up to 45%, demonstrating an inclination towards neutrality amidst possible economic variabilities.

Latest Analyst Recommendations

The latest series of recommendations for Amgen Inc. reflects a sense of continuity within analyst opinions, with most advisory services maintaining their ratings without significant alterations. The steady nature of these ratings underscores sustained, yet cautious market confidence.

Date	New Recommendation	Last Recommendation	Publisher
2026-06-16	Neutral	Neutral	Mizuho
2026-06-10	Equal Weight	Equal Weight	Morgan Stanley
2026-05-14	Overweight	Overweight	Piper Sandler
2026-05-04	Neutral	Neutral	Guggenheim
2026-05-01	Hold	Hold	Truist Securities

Analyst Recommendations with Change of Opinion

While stability characterizes much of Amgen’s recent analyst coverage, there have been some significant changes in opinion. The trend toward downgraded sentiment such as from 'Buy' to 'Hold,' reflects adjustments in broader economic circumstances affecting biotechnology investments.

Date	New Recommendation	Last Recommendation	Publisher
2026-02-12	Hold	Buy	Freedom Broker
2026-01-20	Market Perform	Outperform	Bernstein
2024-10-14	Hold	Buy	Truist Securities
2024-08-07	Equal Weight	Overweight	Wells Fargo
2024-05-03	Equal Weight	Underweight	Barclays

Interpretation

The current analyst views on Amgen Inc. reflect a cautious market perspective amidst broader economic uncertainties. Despite operational stability, the increase in 'Hold' ratings suggests concerns over market fluctuations that could affect biotechnology stocks. Overall, the steadying trend might imply growing caution or neutrality in investment sentiment. However, the consistency in recent ratings indicates a belief in Amgen’s resilience against market dynamics.

Conclusion

Amgen Inc.'s analyst opinion landscape illustrates a conservative approach reflecting broader market uncertainties. Although the firm's robust product line and strategic partnerships offer substantial value, analysts appear mindful of potential economic headwinds affecting the sector. This momentum indicates that while the short-term outlook remains neutral, the long-term potential of Amgen could stay robust, hinging on its scientific innovations and market adaptability.